Clinical Trials Logo
  1. Home
  2. Von Willebrand Disease, Type 1
  3. NCT06064851

Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Von Willebrand Disease Patients — HMB/VWD  

Heavy Menstrual Bleeding Clinical Trial

Official title:
Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With Von Willebrand Disease

Clinical Trial Summary

The objectives of this study are to determine if transcutaneous auricular neurostimulation (tAN) can modulate hemostasis, improve perceived quality of life, and improve pain during the menstrual cycle of von Willebrand Disease (VWD) patients.

Clinical Trial Description

This study is designed as an open label, decentralized clinical study in which patients with VWD and heavy menstrual bleeding (HMB) will receive tAN, which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN). Participants will be enrolled in the study over the course of two consecutive menstrual cycles. During the First Menstruation (baseline), no tAN treatment will be delivered. Participants will estimate blood loss daily throughout the duration of the menstruation phase of their first menstrual cycle. Dysmenorrhea, a general quality of life assessment, and total duration of menstruation will be collected on the final day of first menstruation. During the Second Menstruation, participants will self-administer 2, 1-hour sessions (daily total of 2 hours) of active tAN daily beginning Day 1 of menstruation through the final day of second menstruation. Participants will estimate blood loss daily throughout the duration of the menstruation phase of their second menstruation. Dysmenorrhea, a general quality of life assessment, and total duration of menstruation will be collected on the final day of second menstruation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06064851
Study type Interventional
Source Spark Biomedical, Inc.
Contact Caroline Benner
Phone 210-624-8046
Email hmbstudy@fiveliters.com
Status Recruiting
Phase N/A
Start date October 27, 2023
Completion date September 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02934789 - Effectiveness of Truclear on Patient Quality of Life N/A
Completed NCT02925494 - An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Phase 3
Recruiting NCT04959396 - IUB SEAD RED (Revolutionary Endometrial Ablation Device Study N/A
Active, not recruiting NCT04778072 - A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects N/A
Terminated NCT05026502 - A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
Terminated NCT04132349 - Ulipristal Acetate in Symptomatic Uterine Fibroid Phase 4
Completed NCT00386308 - Efficacy and Safety Study of XP12B in Women With Menorrhagia Phase 3
Completed NCT03412890 - LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Phase 3
Active, not recruiting NCT04477837 - Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
Completed NCT05176496 - A Study Called Champion-HMB to Learn More About Females With Heavy Menstrual Bleeding and Available Treatments to Enable Earlier Diagnosis and to Predict Courses of Treatment
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Completed NCT00401193 - Efficacy and Safety of XP12B in Women With Menorrhagia Phase 3
Completed NCT03317795 - Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Phase 4
Completed NCT02943655 - Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause Phase 3
Completed NCT03070951 - Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids Phase 3
Recruiting NCT05685199 - Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding
Completed NCT05406960 - Therapeutic Effect of Herbal Infusion on Menometrorrhagia N/A
Not yet recruiting NCT05079815 - Heavy Menstrual Bleeding and Iron Deficiency Anemia
Active, not recruiting NCT02449304 - Evaluation of 4th Generation Bipolar Radiofrequency Endometrial Ablation Device Phase 4
Terminated NCT02001324 - HMB- Data Collection Methods N/A